PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORI'	тү		•	ane.
Го:			PCT	anslation
			ITTEN OPINION OF THI ONAL SEARCHING AUT	Е
			(PCT Rule 43bis.1)	
		Date of mailing (day/month/year)	See Form PCT/ (sheet 2)	ISA/210
Applicant's or agent's file reference		FOR FURTHER A		
F1D1081B1W01	1.61.		See paragraph 2 below Priority date (day/month/year)	
International application No. PCT/FR2004/002518	International filing date (шау топпо уейг ј	06.10.2003	
International Patent Classification (IPC) or both A61K7/40, A61K7/48	national classification and	d IPC		
Applicant LABORATOIRE DE DERMO-	-COSMETIQUE	ANIMALE (L	.D.C.A) SAS	
This opinion contains indications related to the second seco	ting to the following items	s:		
Box No. 1 Basis of the				
Box No. II Priority	орнион			
· —	shment of opinion with re	gard to novelty, invent	ive step and industrial applicabi	ility
	ty of invention	B,,	•	
Reasoned st		.1(a)(i) with regard to a	novelty, inventive step or industement	trial
· —	uments cited			
Box No. VII Certain defe	ects in the international ap	plication		
Box No. VIII Certain obs	ervations on the internation	onal application		
2. FURTHER ACTION If a demand for international preli International Preliminary Examining than this one to be the IPEA and the this International Searching Authorit If this opinion is, as provided above	Authority ("IPEA") exce chosen IPEA has notifie y will not be so considered	of that this does not ap d the International Burd.	reau under Rule 66.1 bis(b) that A. the applicant is invited to st	written opinions of
written reply together, where appropriation PCT/ISA/220 or before the expiration	priate, with amendments n of 22 months from the p	, before the expiration	1 Of 3 months from the date	of mailing of Form
For further options, see Form PCT/IS	SA/220.			
3. For further details, see notes to Form	PCT/ISA/220.			
None and mailing address of the ISA/FD		Authorized officer		
Name and mailing address of the ISA/EP				
		Telephone No.		
Facsimile No.	 	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2		

Box	x No. I	Basis of this opinion
1.		regard to the language, this opinion has been established on the basis of the international application in the language in which it was unless otherwise indicated under this item.
		This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under
	-	Rule 12.3 and 23.1(b)).
2.	With	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed attion, this opinion has been established on the basis of:
	a.	type of material
		a sequence listing
		table(s) related to the sequence listing
	b.	format of material
		in written format
		in computer readable form
	c.	time of filing/furnishing
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Add	itional comments:
Ì		

Box	No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	
1.	Statement		
	Novelty	(N) Claims	_ YES
		Claims 1-14	_ NO
	Invention	ve step (IS) Claims	YES
	TUACITIA	ve step (IS) Claims Claims 1-14	- NO
		Cialib + 1.	_
	Industri	ial applicability (IA) Claims 1-14	
		Claims	_ NO
2.	Citations a	and explanations:	
	1	Reference is made to the following documents in the present	
		notification:	
	D1:	WO 02/067878 A (SKINCEUTICALS INC) 6 September 2002 (2002-09-	
		06)	
D2:		DATABASE WPI Derwent Publications Ltd., London, GB;	
		AN 1996-220169 XP002280942 VOLFENZONI I ET AL.: "Face cream"	
		&; RU 2 043 764 C (SYNTH.NAT.FRAGRANCES RES. INST.) 20	
		September 1995 (1995-09-20)	
	D3:	EP 0 278 809 A (ROCHAS PARFUMS) 17 August 1988 (1988-08-17)	
	D4:	EP 0 900 561 A (SHISEIDO CO LTD) 10 March 1999 (1999-03-10)	
	D5:	FR 2 681 783 A (BOURJOIS SA) 2 April 1993 (1993-04-02)	
	D6:	PEPE R C, ET AL (EDS.): International Cosmetic Ingredient	
		Dictionary and Handbook, Vol. 1" 2002, COSMETIC, TOILETRY AND	
	_	FRAGRANCE ASSOCIATION, WASHINGTON DC, USA, XP002280940 NN: "Definitionen und Literatur" EAU DE COLOGNE, [Online]	
	D7:		
		<pre>page 1, XP002280937 Extracted from the Internet: URL:http://www.eau-de-</pre>	
		cologne.com/literatur.html>;	
	D8:	NN: "Canna Body Deo" HANF INFO, [Online] page 1, XP002280938	
	י ס ט	Extracted from the Internet: URL:http://www.chanvre-	
		info.ch/shop/index.php?pro=043004&;cat=4>;	
	D9:	NATURPRÄPARATE G. DIETERICH GMBH: "Franzbranntwein - Gel -	
	27.	Mückenbalsam" HOLZHACKER, [Online] pages 1-3, XP002280939	
		Extracted from the Internet:	
		URL:http://www.holzhacker.de/produkte/sortiment/Franz-	
		branntwein/620191-detail.html>.	

	INTERNATIONAL SEARCHENG AUTHORITI
Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
2	The present application fails to comply with the requirements
	of PCT Article 33(1) since the subject matter of $\frac{\text{claim } 1}{\text{claim } 1}$ does
	not meet the requirement of novelty defined in PCT Article
	33(2):
	features a) = solvent vector, b) = complex of essential oils.
i)	D1 (page 10, example 2) describes a topical composition
	containing extracts of "milk" thistle: a) = ethoxydiglycol,
	propylene glycol, b) =essential oils of ylang ylang, geranium,
	rose, rose absolute, camomile.
	In addition, the composition of example 2 contains grapeseed
	oil, sunflower oil, sesame oil and soybean oil containing
	polyunsaturated essential fatty acids, cucumber extract,
	green tea extract, biosaccharide gum, nylon-12 and alpha-
	tocopherol.
ii)	D2 (abstract) discloses a topical composition containing a)
	ethanol, b) essential oil of hyssop and also a "fragrant
	agent", olive oil, polyvinylpyrrolidone, thickener, a nut
	leaf extract, lanolin, saturated fatty acid esters, and
	kedrov balm.
2 2 2 3	D3 (example 2, pages 5-6; example 6, page 8; example 8, page
iii)	9) discloses cosmetic compositions containing an extract of
	Silybum marianum fruits ("hawthorn", "Sauerdorn", "epine-
	vinette") called "Skinavenger TM", which is a mixture of
	extract of Silybum marianum fruits, and b)=triterpenes of
	essential oils, flavonoids, alpha-tocopherol, and borage oil.
	In examples 1 and 2, the "Skinavenger" is accompanied by
	a)=propylene glycol, b)=fragrance, and shea butter,
	bisabolol, hyaluronic acid, and carboxymethylcellulose.
	Example 6 and example 8 contain "Skinavenger", propylene
	glycol, an "aromatic composition" and evening primrose oil.
	grycor, an aromacro composition and the Jr
iv)	D4 (examples 2, 3, 6, 8; pages 9-11, 13) describes
± v /	compositions for the promotion of collagen production with an
	oak extract.
	our chicago.

Reasoned statement under Rule 43bis.1(a)(l) with regard to novelty, inventive step or industrial applicability; Box No. V citations and explanations supporting such statement b) =fragrance. Example 3 contains a) = acetone, b) = fragrance. Example 6 contains a) = ethanol, dipropylene glycol, methanol, b) =fragrance. Example 8 contains a) = dipropylene glycol, acetone, ethanol, b)=fragrance, in addition to olive oil, tocopherol and polyvinyl alcohol. D5 (tables I-III, pages 6-8) describes a mixture of plant v) oils rich in essential fatty acids (borage oil, woad oil, rapeseed oil, Sisymbrium oil) and, subsequently, cosmetic compositions containing them (example II, tables IV-VI, pages 9-13). These compositions contain a)=solvents such as propylene glycol, glycerol or ethanol, b)=fragrances, and, in addition, allantoin, bisabolol and thickeners. The "International Cosmetic Ingredient Dictionary and vi) Handbook, Vol. 1" is cited as D6, listing a multitude of commercial plant extracts (extracts of essential oils and fruits) in which ethoxydiglycol is used as solvent. In addition, ethoxydiglycol is disclosed as a common ingredient of fragrances. D7 demonstrates that a conventional Eau de Cologne vii) anticipates the subject matter of claim 1: a) =ethanol, b) =citrus fruit oils. viii) The deodorant described in D8 and containing a) =ethanol, b) =hemp essential oil, and "sativa" fragrance (with hemp oil, plant extracts) also anticipates the subject matter of claim 1. The "alcoholic liniment - gel - mosquito balm" compositions ix) of D9 also anticipate the subject matter of claim 1: a) =ethanol, b) =extracts of arnica, (essential) oil of fir, menthol, camphor. The "gel" contains a gelling agent, the balm contains a calmant.

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
3	DEPENDENT CLAIMS 2-14
	The claims do not contain any features which, in combination
	with the features of any claim to which they refer, meet the
	requirements of the PCT in respect of novelty and inventive
	step (PCT Article 33(2) and (3)).

International application No.
PCT/FR2004/002518

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

- References to claim 4 or 7 introduce a lack of clarity and therefore contravene PCT Article 6: Claims 4 and 7 containing the term "consisting of" are to be interpreted "with exclusive definition".
- In claim 3 or 6, the reference to the preceding claim (claims 2 and 5 respectively) is contradictory.
- In claim 3, the substances 2-pyrrolidone and N-methylpyrrolidone do not represent "organic solvents" as claimed.
- 4. The reference to the description in claim 12 (page 16, lines 2-3) contravenes PCT Article 6.